• Vertex in long-term reimbursement agreement with ROI for CF medicines europeanpharmaceuticalreview
    June 12, 2017
    Vertex Pharmaceuticals has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor) for all of the approximately 500 people in Ireland with cystic fibrosis (CF) ages 12 and older who ha
PharmaSources Customer Service